

Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest and Waiver under 18 U.S.C. §208(b)(1)

John Teerlink, M.D.

Committee: Cardiovascular and Renal Drugs Advisory Committee

Meeting Date: April 26, 2006

I acknowledge that contingent upon public disclosure of the financial interests listed below, related to the agenda item concerning the discussion of the Agency's draft recommendations for re-labeling of anti-hypertensive drugs for outcome claims, as a follow-up to the committee's meeting on June 15, 2005, where the committee discussed class labeling of antihypertensive drugs based on the proximity of their data to outcome trials, I am eligible to receive a waiver under 18 U.S.C. §208(b)(1).

Type of Interest	Nature	Magnitude
Unrelated Consulting	Affected Firm	From \$10,001 to \$50,000 per year.
Unrelated Consulting	Affected Firm	From \$10,001 to \$50,000 per year.

I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of these interests, the waiver is not valid.

/s/
Signature of SGE

3/20/06
Date